Sang-We Kim

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhenfeng Zhang, Jae Cheol Lee, Luping Lin et al. · Nature Genetics · 2012 · 1.2K citations

Medicine, Cancer Biology, Oncology +16

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +11

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 953 citations

Medicine, Oncology, Pharmacology +10

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

James Chih‐Hsin Yang, Myung‐Ju Ahn, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2017 · 572 citations · Full text

Medicine, Oncology, Pharmacology +15